Status:
RECRUITING
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
Lead Sponsor:
Lion TCR Pte. Ltd.
Collaborating Sponsors:
Beijing GoBroad Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
Eligibility Criteria
Inclusion
- HCC diagnosis confirmed by histology/ cytology or clinically
- HCC that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies
- Has failed at least one line of systemic therapy for HCC
- ECOG performance status ≤1
- Serum HBsAg positivity
- Child-Pugh A (5 - 7 points)
- Life expectancy of at least 1 year
- HLA profile: HLA-A\*02:01 or HLA-A\*24:02
Exclusion
- Brain metastasis
- Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumors
- Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, TKI therapy, and immunotherapy.
- Use of any investigational product (IP) or investigational medical device within 28 days of study drug administration
- Serum HBV DNA levels ≥ 200 IU/ml at screening
- Serum HBsAg levels ≥ 10,000 IU/ml at screening
- Women who are pregnant or breast-feeding
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06961617
Start Date
June 1 2024
End Date
December 1 2028
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gaobo Boren Hospital
Beijing, China